We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The study findings come just as several other potent HIV preventative drugs — called pre-exposure prophylaxis or PrEP drugs — are entering clinical trials. Read More
Ilaris, approved to treat periodic fever syndromes and arthritis in children, also recently struck out as a COVID-19 treatment and a heart disease therapy. Read More
Should the final data support it, the goal would be to make more doses available more quickly if a subset of patients didn’t need a second shot. Read More
Vir Biotechnology and GlaxoSmithKline’s monoclonal antibody for COVID-19 reduced hospitalizations or death from the infection by 85 percent in a phase 3 trial, according to the companies — and they have stopped enrollment in the trial because of the therapy’s “profound efficiency.” Read More
Roche reported that its arthritis drug Actemra (tocilizumab), when paired with the antiviral remdesivir (Veklury) from Gilead Sciences, did not meet the endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia. Read More
Pfizer and BioNTech announced yesterday that their vaccine was 94 percent effective in preventing asymptomatic COVID-19 infection, based on real-world data from Israel, indicating it could greatly reduce transmission from person to person. Read More
Eli Lilly said its combination antibody therapy, bamlanivimab and etesevimab, reduced the risk of hospitalization and death by 87 percent in a late-stage study of 769 high-risk COVID-19 patients — and worked against emerging variant strains of the coronavirus. Read More
The Pfizer/BioNTech COVID-19 vaccine demonstrated effectiveness against a Brazilian coronavirus strain that has quickly spread throughout the country, a study has found. Read More
Researchers found that plasma samples had six times less neutralizing capacity against the Brazilian strain than against the UK and South African strains. Read More
“While we are disappointed that BRII-196 and BRII-198 have not shown clear benefits during the interim analysis … we remain committed to investigating this antibody combination in ambulatory COVID-19 patients through the ongoing ACTIV-2 trial,” said Brii Biosciences CEO Zhi Hong. Read More